MX2009011155A - Derivados de indazol oxadiazol sustituidos para su uso como agonistas de esfingosina-1-fosfato (s1p). - Google Patents
Derivados de indazol oxadiazol sustituidos para su uso como agonistas de esfingosina-1-fosfato (s1p).Info
- Publication number
- MX2009011155A MX2009011155A MX2009011155A MX2009011155A MX2009011155A MX 2009011155 A MX2009011155 A MX 2009011155A MX 2009011155 A MX2009011155 A MX 2009011155A MX 2009011155 A MX2009011155 A MX 2009011155A MX 2009011155 A MX2009011155 A MX 2009011155A
- Authority
- MX
- Mexico
- Prior art keywords
- sphingosine
- agonists
- phosphate
- indazole derivatives
- substituted indazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención proporciona compuestos de la fórmula (I) o sales de los mismos: (ver fórmula I) que tienen actividad farmacológica, procedimientos para su preparación, composiciones farmacéuticas que los contienen y el uso de los mismos en el tratamiento de diferentes trastornos mediados por los receptores S1 P1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0707617A GB0707617D0 (en) | 2007-04-19 | 2007-04-19 | Compounds |
GB0805993A GB0805993D0 (en) | 2008-04-02 | 2008-04-02 | Compounds |
PCT/EP2008/054647 WO2008128951A1 (en) | 2007-04-19 | 2008-04-17 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009011155A true MX2009011155A (es) | 2009-10-30 |
Family
ID=39604751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009011155A MX2009011155A (es) | 2007-04-19 | 2008-04-17 | Derivados de indazol oxadiazol sustituidos para su uso como agonistas de esfingosina-1-fosfato (s1p). |
Country Status (25)
Country | Link |
---|---|
US (1) | US8324254B2 (es) |
EP (1) | EP2137181B1 (es) |
JP (1) | JP5313229B2 (es) |
KR (1) | KR20090130062A (es) |
AR (1) | AR066095A1 (es) |
AT (1) | ATE500252T1 (es) |
AU (1) | AU2008240773B2 (es) |
BR (1) | BRPI0809472A2 (es) |
CA (1) | CA2684385A1 (es) |
CL (1) | CL2008001099A1 (es) |
CO (1) | CO6321136A2 (es) |
CR (1) | CR11119A (es) |
DE (1) | DE602008005285D1 (es) |
DO (1) | DOP2009000237A (es) |
EA (1) | EA016443B1 (es) |
HK (1) | HK1138001A1 (es) |
IL (1) | IL200870A (es) |
JO (1) | JO2686B1 (es) |
MA (1) | MA31311B1 (es) |
MX (1) | MX2009011155A (es) |
MY (1) | MY146606A (es) |
NZ (1) | NZ579595A (es) |
PE (1) | PE20090150A1 (es) |
TW (1) | TWI408137B (es) |
WO (1) | WO2008128951A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0709866B8 (pt) | 2006-04-03 | 2021-05-25 | Astellas Pharma Inc | compostos héteros e composição farmacêutica compreendendo ditos compostos |
JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
AU2008338965A1 (en) * | 2007-12-18 | 2009-06-25 | Arena Pharmaceuticals, Inc. | Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
AR070986A1 (es) * | 2008-04-04 | 2010-05-19 | Lilly Co Eli | Compuesto de 3-indazoil-4 -piridilisotiazoles, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para tratar la ansiedad |
GB0807910D0 (en) * | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
JP5878015B2 (ja) * | 2008-07-23 | 2016-03-08 | ノバルティス アーゲー | スフィンゴシン一リン酸受容体調節因子および筋肉炎症を治療するためのその使用 |
EP2326621B1 (en) | 2008-07-23 | 2016-06-08 | Arena Pharmaceuticals, Inc. | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS |
KR101660059B1 (ko) | 2008-08-22 | 2016-09-26 | 박스알타 인코퍼레이티드 | 중합체 벤질 카르보네이트-유도체 |
RS54970B1 (sr) | 2008-08-27 | 2016-11-30 | Arena Pharm Inc | Supstituisani triciklični derivati kiselina kao s1p1 receptor agonisti korisni pri lečenju autoimunih i upalnih poremećaja |
US8536185B2 (en) | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
AU2009327133B2 (en) | 2008-12-18 | 2016-04-14 | Merck Serono S.A. | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis |
GB0910691D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
GB0910689D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
US8399451B2 (en) * | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
EP2513095A4 (en) * | 2009-12-18 | 2013-05-15 | Glaxo Group Ltd | OXADIAZOLSUBSTITUTED INDAZONE DERIVATIVES FOR USE AS SPHINGOSIN-1-PHOSPHATE-1 (S1P1) RECEPTOR AGONISTS |
EP3378854B1 (en) | 2010-01-27 | 2022-12-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
CA2862375A1 (en) * | 2012-02-03 | 2013-08-08 | Novartis Ag | Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester |
JP2016028016A (ja) * | 2012-12-12 | 2016-02-25 | 大日本住友製薬株式会社 | オキサジアゾール誘導体とその医薬用途 |
CN105474014B (zh) * | 2013-08-20 | 2017-04-05 | 明治制果药业株式会社 | S1p1受体激动剂的评价方法和筛选方法 |
AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
SI3310760T1 (sl) | 2015-06-22 | 2023-02-28 | Arena Pharmaceuticals, Inc. | Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1 |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
MA47503A (fr) | 2017-02-16 | 2021-04-21 | Arena Pharm Inc | Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales |
CN109100971B (zh) * | 2018-08-20 | 2024-02-09 | 合肥华耀电子工业有限公司 | 一种带互锁功能的开关机时序控制电路 |
US11555015B2 (en) | 2018-09-06 | 2023-01-17 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3939238A1 (de) | 1989-11-28 | 1991-05-29 | Bayer Ag | Heterocyclisch substituierte acrylsaeureester |
US5462943A (en) * | 1990-01-28 | 1995-10-31 | Bayer Aktiengesellschaft | Substituted acetic acid esters useful as pesticides per se and as intermediates for substitued acrylic esters pesticides |
DE4002466A1 (de) * | 1990-01-28 | 1991-10-10 | Bayer Ag | Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester |
US5262416A (en) * | 1990-01-28 | 1993-11-16 | Bayer Aktiengesellschaft | Pesticidal substituted 2-[6-(pyrimidinyl)-indol-1-yl]-acrylic esters |
US5523312A (en) | 1994-09-27 | 1996-06-04 | Sterling Winthrop Inc. | Antipicornaviral agents |
JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
JP2001199983A (ja) * | 2000-01-18 | 2001-07-24 | Teijin Ltd | ベンズイミダゾール誘導体 |
EP1549640A4 (en) | 2002-06-17 | 2008-08-06 | Merck & Co Inc | 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS |
CA2523677A1 (en) * | 2003-04-30 | 2004-11-11 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
CA2524867A1 (en) * | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
US20070043014A1 (en) * | 2003-10-01 | 2007-02-22 | Merck & Co., Inc. | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
WO2005058848A1 (en) | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
WO2006047195A2 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
JP5024039B2 (ja) | 2005-02-25 | 2012-09-12 | 小野薬品工業株式会社 | インドール化合物およびその用途 |
MX2007011672A (es) * | 2005-03-23 | 2007-11-15 | Actelion Pharmaceuticals Ltd | Nuevos derivados de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1. |
DE602006015297D1 (de) | 2005-04-22 | 2010-08-19 | Daiichi Sankyo Co Ltd | 3-azetidincarbonsäure-derivate zur verwendung als immunsuppressiva |
JP2008545767A (ja) * | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 多環式オキサジアゾールまたはイソキサゾールおよびsip受容体リガンドとしてのそれらの使用 |
AU2006283175A1 (en) * | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
GB0601744D0 (en) * | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
BRPI0709866B8 (pt) * | 2006-04-03 | 2021-05-25 | Astellas Pharma Inc | compostos héteros e composição farmacêutica compreendendo ditos compostos |
JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
-
2008
- 2008-04-17 CL CL200801099A patent/CL2008001099A1/es unknown
- 2008-04-17 TW TW097113880A patent/TWI408137B/zh not_active IP Right Cessation
- 2008-04-17 EA EA200970967A patent/EA016443B1/ru not_active IP Right Cessation
- 2008-04-17 AR ARP080101584A patent/AR066095A1/es not_active Application Discontinuation
- 2008-04-17 WO PCT/EP2008/054647 patent/WO2008128951A1/en active Application Filing
- 2008-04-17 AU AU2008240773A patent/AU2008240773B2/en not_active Expired - Fee Related
- 2008-04-17 JP JP2010503494A patent/JP5313229B2/ja not_active Expired - Fee Related
- 2008-04-17 MY MYPI20094368A patent/MY146606A/en unknown
- 2008-04-17 BR BRPI0809472-1A patent/BRPI0809472A2/pt not_active IP Right Cessation
- 2008-04-17 MX MX2009011155A patent/MX2009011155A/es active IP Right Grant
- 2008-04-17 AT AT08736315T patent/ATE500252T1/de not_active IP Right Cessation
- 2008-04-17 JO JO2008183A patent/JO2686B1/en active
- 2008-04-17 NZ NZ579595A patent/NZ579595A/en not_active IP Right Cessation
- 2008-04-17 DE DE602008005285T patent/DE602008005285D1/de active Active
- 2008-04-17 KR KR1020097021613A patent/KR20090130062A/ko not_active Application Discontinuation
- 2008-04-17 PE PE2008000672A patent/PE20090150A1/es not_active Application Discontinuation
- 2008-04-17 CA CA002684385A patent/CA2684385A1/en not_active Abandoned
- 2008-04-17 US US12/596,488 patent/US8324254B2/en not_active Expired - Fee Related
- 2008-04-17 EP EP08736315A patent/EP2137181B1/en not_active Not-in-force
-
2009
- 2009-09-10 IL IL200870A patent/IL200870A/en not_active IP Right Cessation
- 2009-10-08 DO DO2009000237A patent/DOP2009000237A/es unknown
- 2009-10-15 MA MA32280A patent/MA31311B1/fr unknown
- 2009-10-16 CO CO09115828A patent/CO6321136A2/es active IP Right Grant
- 2009-11-19 CR CR11119A patent/CR11119A/es not_active Application Discontinuation
-
2010
- 2010-04-29 HK HK10104250.5A patent/HK1138001A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CL2008001099A1 (es) | 2008-10-24 |
AU2008240773A1 (en) | 2008-10-30 |
IL200870A0 (en) | 2010-05-17 |
JP5313229B2 (ja) | 2013-10-09 |
CO6321136A2 (es) | 2011-09-20 |
EP2137181A1 (en) | 2009-12-30 |
JO2686B1 (en) | 2013-03-03 |
HK1138001A1 (en) | 2010-08-13 |
AR066095A1 (es) | 2009-07-22 |
CA2684385A1 (en) | 2008-10-30 |
JP2010524886A (ja) | 2010-07-22 |
NZ579595A (en) | 2012-06-29 |
MY146606A (en) | 2012-09-14 |
WO2008128951A1 (en) | 2008-10-30 |
EP2137181B1 (en) | 2011-03-02 |
MA31311B1 (fr) | 2010-04-01 |
TWI408137B (zh) | 2013-09-11 |
US20100113528A1 (en) | 2010-05-06 |
ATE500252T1 (de) | 2011-03-15 |
US8324254B2 (en) | 2012-12-04 |
CR11119A (es) | 2010-01-18 |
DOP2009000237A (es) | 2010-05-31 |
DE602008005285D1 (de) | 2011-04-14 |
KR20090130062A (ko) | 2009-12-17 |
PE20090150A1 (es) | 2009-05-08 |
AU2008240773B2 (en) | 2013-10-03 |
EA200970967A1 (ru) | 2010-02-26 |
IL200870A (en) | 2013-08-29 |
EA016443B1 (ru) | 2012-05-30 |
BRPI0809472A2 (pt) | 2014-09-09 |
TW200911794A (en) | 2009-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY146606A (en) | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists | |
MY148470A (en) | Indole derivatives as s1p1 receptor agonists | |
PT2150530E (pt) | Derivados de sulfonamida substituídos | |
HK1142062A1 (en) | Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) | |
DE602007009420D1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
EA201000024A1 (ru) | Новые производные дикарбоновых кислот в качестве агонистов рецептора s1p1 | |
CL2008002129A1 (es) | Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer. | |
UY32156A (es) | Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones. | |
EA201100030A1 (ru) | Пиразольные соединения 436 | |
TW200801029A (en) | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | |
NZ588830A (en) | Inhibitors of protein kinases | |
MX2019011904A (es) | Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos. | |
MX346186B (es) | Inhibidores de proteina cinasas. | |
MX2013008296A (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
DE602006018713D1 (de) | Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate | |
GEP20135806B (en) | Lactams as beta secretase inhibitors | |
MX2010009756A (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos. | |
ZA200810031B (en) | 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use for the manufacture of medicaments | |
EA201100502A1 (ru) | Гликозидные производные и их применения | |
MY148732A (en) | Triazolium salts as par1 inhibitors, production thereof, and use as medicaments | |
MX2012015021A (es) | 5-(bifenil-4-il)-3-fenil-1, 2, 4-oxidiazolil derivados como ligandos en los receptores esfingosina-1-fosfato (s1p). | |
GB0609897D0 (en) | Compounds | |
UA102508C2 (ru) | Производные индола как агонисты рецептора s1p1 | |
EP2563785A4 (en) | Compounds as Agonists Against S1P1 Receptors | |
WO2013074905A3 (en) | Compounds, compositions, pharmaceutical compositions, and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |